Jochen Sven Utikal, MD
Jochen Sven Utikal, MD
Professor for Dermatooncology, German Cancer Research Center and University Medical Center Mannheim
確認したメール アドレス: dkfz.de
タイトル
引用先
引用先
Improved survival with MEK inhibition in BRAF-mutated melanoma
KT Flaherty, C Robert, P Hersey, P Nathan, C Garbe, M Milhem, ...
New England Journal of Medicine 367 (2), 107-114, 2012
21322012
Induced pluripotent stem cells generated without viral integration
M Stadtfeld, M Nagaya, J Utikal, G Weir, K Hochedlinger
Science 322 (5903), 945-949, 2008
20722008
Directly reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue contribution
N Maherali, R Sridharan, W Xie, J Utikal, S Eminli, K Arnold, M Stadtfeld, ...
Cell stem cell 1 (1), 55-70, 2007
20492007
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
EM Van Allen, D Miao, B Schilling, SA Shukla, C Blank, L Zimmer, ...
Science 350 (6257), 207-211, 2015
16252015
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma
GV Long, D Stroyakovskiy, H Gogas, E Levchenko, F de Braud, J Larkin, ...
New England Journal of Medicine 371 (20), 1877-1888, 2014
14352014
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
U Sahin, E Derhovanessian, M Miller, BP Kloke, P Simon, M Löwer, ...
Nature 547 (7662), 222-226, 2017
10982017
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
GV Long, D Stroyakovskiy, H Gogas, E Levchenko, F De Braud, J Larkin, ...
The Lancet 386 (9992), 444-451, 2015
10892015
Immortalization eliminates a roadblock during cellular reprogramming into iPS cells
J Utikal, JM Polo, M Stadtfeld, N Maherali, W Kulalert, RM Walsh, A Khalil, ...
Nature 460 (7259), 1145-1148, 2009
9662009
A high-efficiency system for the generation and study of human induced pluripotent stem cells
N Maherali, T Ahfeldt, A Rigamonti, J Utikal, C Cowan, K Hochedlinger
Cell stem cell 3 (3), 340-345, 2008
6452008
Reprogramming of neural progenitor cells into induced pluripotent stem cells in the absence of exogenous Sox2 expression
S Eminli, J Utikal, K Arnold, R Jaenisch, K Hochedlinger
Stem cells 26 (10), 2467-2474, 2008
4512008
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy
L Hofmann, A Forschner, C Loquai, SM Goldinger, L Zimmer, S Ugurel, ...
European journal of cancer 60, 190-209, 2016
4502016
Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy
L Zimmer, SM Goldinger, L Hofmann, C Loquai, S Ugurel, I Thomas, ...
European journal of cancer 60, 210-225, 2016
4032016
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
GV Long, KT Flaherty, D Stroyakovskiy, H Gogas, E Levchenko, ...
Annals of Oncology 28 (7), 1631-1639, 2017
3942017
Sox2 is dispensable for the reprogramming of melanocytes and melanoma cells into induced pluripotent stem cells
J Utikal, N Maherali, W Kulalert, K Hochedlinger
Journal of cell science 122 (19), 3502-3510, 2009
3502009
Targeting myeloid-derived suppressor cells to bypass tumor-induced immunosuppression
V Fleming, X Hu, R Weber, V Nagibin, C Groth, P Altevogt, J Utikal, ...
Frontiers in immunology 9, 398, 2018
2452018
Mφ1 and Mφ2 can be re-polarized by Th2 or Th1 cytokines, respectively, and respond to exogenous danger signals
A Gratchev, J Kzhyshkowska, K Köthe, I Muller-Molinet, S Kannookadan, ...
Immunobiology 211 (6-8), 473-486, 2006
2372006
Myeloid cells and related chronic inflammatory factors as novel predictive markers in melanoma treatment with ipilimumab
C Gebhardt, A Sevko, H Jiang, R Lichtenberger, M Reith, K Tarnanidis, ...
Clinical Cancer Research 21 (24), 5453-5459, 2015
2302015
The role of myeloid-derived suppressor cells (MDSC) in cancer progression
V Umansky, C Blattner, C Gebhardt, J Utikal
Vaccines 4 (4), 36, 2016
2152016
Myeloid-derived suppressor cells hinder the anti-cancer activity of immune checkpoint inhibitors
R Weber, V Fleming, X Hu, V Nagibin, C Groth, P Altevogt, J Utikal, ...
Frontiers in immunology 9, 1310, 2018
2122018
SOX2 and cancer: current research and its implications in the clinic
K Weina, J Utikal
Clinical and translational medicine 3 (1), 1-10, 2014
2062014
現在システムで処理を実行できません。しばらくしてからもう一度お試しください。
論文 1–20